Glioblastoma Clinical Trials

78 studies are recruiting for glioblastoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

   Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnose…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   63 in total

   Run by

   Global Coalition for Adaptive Research

   See if you can join NCT03970447 on ClinicalTrials.gov

2. Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

   Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) w…

   Stage

   Phase 1

   Ages

   3 to 25

   Site

   Augusta University, Georgia Cancer Center, Augusta, Georgia

   Run by

   Theodore S. Johnson

   See if you can join NCT05106296 on ClinicalTrials.gov

3. Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients

   This clinical trial tests the impact of tear fluid in detecting tumor-associated extracellular vesicles (TEVs) in patients with glioblastoma. Brain tumors release small particles, called TEVs, that may provide information about the tumor, including how it responds to treatment. These particles can …

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT07775534 on ClinicalTrials.gov

4. Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

   The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   National Institutes of Health, Bethesda, Maryland

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT04541082 on ClinicalTrials.gov

5. Implantable Microdevice In Primary Brain Tumors

   This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors. * The device involved in this study is called a microdevice. * The drugs used in this study…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Run by

   Oliver Jonas

   See if you can join NCT04135807 on ClinicalTrials.gov

6. Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma

   The purpose of this study is to determine the effect of Lixumistat in patients with newly diagnosed Glioblastoma.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   Macarena De La Fuente, MD

   See if you can join NCT07884344 on ClinicalTrials.gov

7. A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

   This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. BDTX-1535 is being tested in this study to see if it can be …

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Chandler Regional Medical Center, Chandler, Arizona

   Locations

   2 in total

   Run by

   St. Joseph's Hospital and Medical Center, Phoenix

   See if you can join NCT06072586 on ClinicalTrials.gov

8. PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

   Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the brain and spinal cord will die within 5 years. Many of these people have …

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06161519 on ClinicalTrials.gov

9. Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

   This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Eben Rosenthal

   See if you can join NCT07493447 on ClinicalTrials.gov

10. Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.

    Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well. After radiation, MRI scans can be harder to understand because radiation changes how the brain looks on th…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    Cooper University HealthCare, Camden, New Jersey

    Run by

    The Cooper Health System

    See if you can join NCT07439172 on ClinicalTrials.gov

11. TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

    This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete th…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    Dent Neurologic Institute, Buffalo, New York

    Run by

    Alpheus Medical, Inc.

    See if you can join NCT07862647 on ClinicalTrials.gov

12. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

    The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the bloo…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Phoenix, Arizona

    Locations

    56 in total

    Run by

    CarThera

    See if you can join NCT05902169 on ClinicalTrials.gov

13. Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

    This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation of Arm A:Arm B. * A Perioperative/Operative Phase where patie…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona

    Locations

    13 in total

    Run by

    GT Medical Technologies, Inc.

    See if you can join NCT07195591 on ClinicalTrials.gov

14. Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

    The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to t…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Baptist Health Herbert Wertheim Cancer Institute, Miami, Florida

    Locations

    2 in total

    Run by

    Baptist Health South Florida

    See if you can join NCT06991101 on ClinicalTrials.gov

15. The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

    This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medica…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT07285044 on ClinicalTrials.gov

16. Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

    This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-rela…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California Davis Comprehensive Cancer Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT07145112 on ClinicalTrials.gov

17. VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

    The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated g…

    Stage

    Phase 2

    Ages

    18 to 98

    Site

    Inova Schar Cancer, Fairfax, Virginia

    Run by

    Inova Health Care Services

    See if you can join NCT07831369 on ClinicalTrials.gov

18. REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma

    REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma. Participants will be consented before starting standard-of-care concurrent temozolomide and radiotherapy. After enrollment, participants will enter an observational lead…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Minnesota Radiation Oncology, Minneapolis, Minnesota

    Run by

    University of Minnesota

    See if you can join NCT07831772 on ClinicalTrials.gov

19. ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

    This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or gliosarcoma that can be removed by surgery (resectable) and that is growing, spr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

    Locations

    2 in total

    Run by

    Jonsson Comprehensive Cancer Center

    See if you can join NCT07089641 on ClinicalTrials.gov

20. A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

    Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standa…

    Stage

    Phase 1

    Ages

    19 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT05698524 on ClinicalTrials.gov

21. Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

    * To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer [18F]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

    Locations

    2 in total

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT06613841 on ClinicalTrials.gov

22. Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

    The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Los Angeles (Data Collection Only), Los Angeles, California

    Locations

    11 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06934889 on ClinicalTrials.gov

23. Targeted Pediatric High-Grade Glioma Therapy

    The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

    Stage

    Not phased

    Ages

    1 to 39

    Site

    Children's National Medical Center, Washington D.C., District of Columbia

    Locations

    22 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05839379 on ClinicalTrials.gov

24. Serial MRI Scans During Radiation Therapy

    This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulv…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham and Women Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04188535 on ClinicalTrials.gov

25. INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

    This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    12 in total

    Run by

    David Reardon, MD

    See if you can join NCT02977780 on ClinicalTrials.gov